XSHG
600085
Market cap4.90bUSD
Oct 09, Last price
24.28CNY
1D
1.46%
1Q
2.53%
Jan 2017
-22.55%
Name
Beijing Tongrentang Co Ltd
Chart & performance
P/E
28.00
P/S
1.93
EPS
0.87
Div yield, %
2.09%
Shrs. gr., 5y
—
Rev. gr., 5y
6.11%
Revenues
17.26b
-7.21%
Net income
1.19b
-22.07%
CFO
2.69b
+253.87%
Dividend
Jul 01, 20260.5 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beijing Tongrentang Co., Ltd engages in the production and sale of traditional Chinese medicine preparations in China and internationally. The company offers various product dosage forms, such as pills, powders, medicated wines, capsules, oral liquids, and drop pills. Its products are used for cardiovascular, cerebrovascular, gynecology, heat-clearing, respiratory system, nourishing and calming, digestive, pediatrics, wind-dispelling and dampness removing, orthopedics, facial features, dermatological surgery, mental health, and food and beverages applications. The company was founded in 1997 and is based in Beijing, China. Beijing Tongrentang Co., Ltd operates as a subsidiary of China Beijing Tong Ren Tang Group Co. Ltd.
Key people
Zhiqiang Tang
General Counsel · since 2022
Jiafu Chen
General Manager, Director · since 2025
Lingyun Dong
Deputy General Manager · since 2024
Li Feng
Deputy General Manager, Secretary of the Board · since 2022
Tian Wang
Deputy General Manager · since 2019
Dongmei Huang
Director · since 2024
Baoxia Pan
Chief Accounting Officer, Director · since 2025
Xingwu Wang
Director · since 2025
Chunrui Wang
Director · since 2024
Li Yang
Director · since 2024
Zhaohua Zhang
Chairman of the Board · since 2025
Yanjiang Qiao
Independent Director · since 2021
Independent Director · since 2021
Zhao Wang
Independent Director · since 2021
Qingying Yang
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||